Edition:
United Kingdom

Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

0.95USD
15 Dec 2017
Change (% chg)

$0.05 (+5.61%)
Prev Close
$0.90
Open
$0.90
Day's High
$0.95
Day's Low
$0.90
Volume
79,290
Avg. Vol
118,071
52-wk High
$2.75
52-wk Low
$0.79

Latest Key Developments (Source: Significant Developments)

Regulus Therapeutics Q3 loss per share $0.18
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Regulus Therapeutics Inc ::Regulus reports third quarter 2017 financial results and recent events.Q3 revenue was less than $100,000.Q3 loss per share $0.18.Q3 revenue view $864,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Regulus Q3 loss per share $0.18
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Regulus Therapeutics Inc ::Regulus reports third quarter 2017 financial results and recent events.Q3 revenue $100,000.Q3 loss per share $0.18.Q3 revenue view $864,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Regulus Therapeutics q2 loss per share $0.40
Tuesday, 2 Aug 2016 

Regulus Therapeutics Inc : Q2 loss per share $0.40 . On track to deliver follow-up results from rg-101 studies while working to address deficiencies outlined in by fda . Qtrly revenue was $0.5 million compared with $3.8 million .Initiating a phase ii study in alport syndrome for rg-012, and plan to nominate our fourth clinical candidate by year-end.  Full Article

Regulus says working to resolve issues outlined in letter from US FDA about clinical hold
Wednesday, 27 Jul 2016 

Regulus Therapeutics Inc : Received written communication from u.s. FDA outlining information required to resolve clinical hold for its IND for RG-101 . Says On Track To Deliver Follow Up results from on-going RG-101 studies . Working to resolve issues outlined in letter and anticipate a decision from FDA in q4 . "we remain on track to deliver follow-up results from ongoing rg-101 studies" . Fda requested detailed safety data analysis from preclinical and clinical studies among other things . Fda will notify regulus of its decision within 30 days of receipt of complete response to issues .Timelines of on-going studies have not been impacted by clinical hold.  Full Article

Regulus Therapeutics reports clinical hold of RG-101
Monday, 27 Jun 2016 

Regulus Therapeutics Inc : Regulus reports clinical hold of RG-101 . Says Regulus remains on track to deliver follow-up results from these studies at upcoming relevant scientific meetings . Timelines of on-going studies are not expected to be impacted . Regulus anticipates it will receive a formal clinical hold letter from fda within 30 days .FDA initiated clinical hold after regulus reported a second serious adverse event (sae) of jaundice.  Full Article

Regulus secures $30 mln growth capital credit facility
Monday, 20 Jun 2016 

Regulus Therapeutics Inc : Says has entered into a $30 million loan and security agreement with Oxford Finance Llc . Says proceeds from loan will be used to provide additional working capital for advancement of clinical and pre-clinical development pipeline .Regulus secures $30 million growth capital credit facility.  Full Article

Regulus Therapeutics rpeorts top-line results
Tuesday, 7 Jun 2016 

Regulus Therapeutics Inc : Line results from primary endpoint analysis of phase II studies of RG-101 for treatment of hepatitis C virus infection .Says RG-101 in combination with four weeks of oral daa therapy has been generally well tolerated.  Full Article

Regulus expands clinical trial collaboration with GSK
Wednesday, 1 Jun 2016 

Regulus Therapeutics Inc : Ongoing phase ii rg-101 and oral gsk2878175 combination study on track to report interim results by year-end .Regulus expands clinical trial collaboration with gsk.  Full Article

BRIEF-Regulus Therapeutics Q3 loss per share $0.18

* Regulus reports third quarter 2017 financial results and recent events